SBIR/STTR Research Award

Trunkamide Optimization as a Demonstration of a Revolutionary Drug Discovery/Deve

Award identifier ab0591f668952b157176efd365c735b15c2f1dd4e76ae3422d25ec41984df5c1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$199,720

Program and phase

SBIR · Phase I

Award year

2010

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SYMBION DISCOVERY INCORPORATED
Proposal award date
Not reported
Contract end date
Not reported
UEI
KV9HB2DMNK47
Solicitation number
PHS2010-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Project Summary/Abstract : Natural products still comprise the majority of therapeutic agents. However, they suffer from a difficulty in the creation of derivatives, and they can also be hard to supply. Derivatives are extremely important in the optimization of properties, such as toxicity or solubility, which are critical to development of therapeutics. Recently, it has become increasingly popular to create libraries of derivatives using genetic engineering of natural product biosynthetic genes. Even in the best libraries, the numbers of derivatives are in the hundreds or low thousands. Recently, we discovered an evolutionary pathway that could potentially be harvested to generate up to billions of derivatives. The compounds can be rapidly evolved to improve desired properties while minimizing unwanted effects. We have developed a system in which new activities can be pharmacologically optimized in a matter of days to weeks, exploring a huge diversity of unnatural natural products. In this project, we will develop this system and provide a practical proof-of-concept using the potential anticancer natural product, Trunkamide, as a model. As a practical proof-of-concept, we will optimize the anticancer cyanobactin natural product, Trunkamide, which is a potential clinical agent that requires optimization. Our aims here are to: 1) Demonstrate the application of engineered cyanobactin libraries to high throughput screening and to problems of ADME/Tox. 2) Optimize the activity and pharmacological properties of a known pre-clinical anticancer candidate cyanobactin, Trunkamide, for clinical development. PUBLIC HEALTH RELEVANCE: Project Narrative: We will use innovative new technology to develop optimized anticancer agents with new mechanisms. The underlying technology to be developed has broad application in the treatment of human diseases, especially those involving infective agents or protein interactions.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2010). Reported award amounts total $468,052. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.